FEATURES OF PIRIBEDIL USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENTS IN PATIENTS WITH CHRONIC HEART FAILURE

Abstract

Aim: To study the features of piribedil use in the treatment of mild cognitive impairments in patients with chronic heart failure (CHF). Material and methods: Open randomized study of piribedil efficacy in treatment of mild cognitive impairments of the patients with CHF and ischemic heart disease was performed. Eligible patients were randomized into group of piribedil treatment or control group. Each group included 20 patients. Patients of the main group received piribedil 50 mg a day during 12 weeks. Cognitive functions were estimated by Burdon's test, 5 and 7 subtests of Wexler before and after 12 weeks of treatment. Results: Significant improvement of cognitive tests was revealed in patients receiving piribedil at the final visit. Maximum effect of the drug was observed in younger patients, patients with increased carotid arteries intima-media thickness and increased left ventricular end-diastolic dimension. Conclusion: Piribedil significantly improves memory and attention in patients with CHF and can be used in therapy of mild cognitive impairments in these patients.